Lv62
1960 积分 2022-06-10 加入
MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment
18小时前
已完结
2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline*
10天前
已完结
Dyslipidemia Update
11天前
已完结
Dyslipidemia
11天前
已完结
Dyslipidemia
11天前
已完结
Quercetin inhibits platelet activation and ER-stress mediated autophagy in response to extracellular histone
1个月前
已完结
Quercetin Inhibits Platelet Activation and ER-stress Mediated Autophagy in Response to Extracellular Histone
1个月前
已完结
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial
2个月前
已完结
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial
2个月前
已完结
MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment
3个月前
已完结
皖公网安备34019202002308
